(Q24241646)

1

0 references

Mónica Rengifo-Pardo

3

0 references

Antonio Macaya

4

0 references

Jorge Alvar

5

0 references

John A Tweed

Cochrane Database of Systematic Reviews

6

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

Randomized, Double‐Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony‐Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Skin reactivity to thimerosal and phenol-preserved Montenegro antigen in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Mefloquine in the treatment of cutaneous leishmaniasis in an endemic area of Leishmania (Viannia) braziliensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Effect of salt supplementation on amphotericin B nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Leishmaniasis and poverty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

The relationship between leishmaniasis and AIDS: the second 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Immunotherapy for drug-refractory mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Treatment of New World cutaneous and mucosal leishmaniases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Liposomal amphotericin B for the treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Epidemiological surveys confirm an increasing burden of cutaneous leishmaniasis in north-east Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Appraising systematic reviews and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

The epidemiology and control of leishmaniasis in Andean countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Leishmaniasis. Public health aspects and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Parasitological diagnosis of mucocutaneous leishmaniasis due to Leishmania b. braziliensis in Bolivia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

When are randomised trials unnecessary? Picking signal from noise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Interventions for Old World cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Beware the "Texas sharp shooter" in rate ratios of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Management of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Cutaneous leishmaniasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Cutaneous leishmaniasis in the Metropolitan Region of Belo Horizonte: clinical, laboratorial, therapeutic and prognosis features (1989-1995)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Efficacy of azithromycin in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Strategic emphases for tropical diseases research: a TDR perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Out-patient parenteral antimicrobial therapy--a viable option for the management of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Challenges and new discoveries in the treatment of leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Risk factors for mucosal manifestation of American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Strategic emphases for tropical diseases research: a TDR perspective

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Allopurinol in the Treatment of American Cutaneous Leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

The Vancouver Scar Scale: an administration tool and its interrater reliability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Comparative studies of the detection rates of Leishmania parasites from formalin, ethanol-fixed, frozen human skin specimens by polymerase chain reaction and Southern blotting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Cutaneous leishmaniasis from Belize--treatment with ketoconazole

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Oral Ketoconazole in the Treatment of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Treatment of cutaneous leishmaniasis with infrared heat

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

[Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

[Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

[Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

[Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

PCR detection and identification of Leishmania parasites in clinical specimens in Ecuador: a comparison with classical diagnostic methods

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Effect of Temperature on Multiplication of Leishmania Amastigotes within Human Monocyte-Derived Macrophages in Vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Observations on Local Heat Treatment for Cutaneous Leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Placebo Controlled Treatment of Ecuadorian Cutaneous Leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Treatment of mucosal leishmaniasis in Latin America: systematic review.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004834.PUB2

7 January 2021

10.1002/14651858.CD004834.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2632245

OpenCitations bibliographic resource ID

2632245

1 reference